Sandbox Reserved 1160: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 47: | Line 47: | ||
== External Resources == | == External Resources == | ||
[http://www.fraxa.org/novartis-discontinues-development-mavoglurant-afq056-fragile-x-syndrome/ Novartis Fragile X trials] | [http://www.fraxa.org/novartis-discontinues-development-mavoglurant-afq056-fragile-x-syndrome/ Novartis Fragile X trials] | ||
[http://www.researchgate.net/publication/263354624_Mavoglurant_as_a_treatment_for_Parkinson's_disease Mavoglurant as a treatment for Parkinson's disease] | |||
[http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293 Pharmacology of mGlu5 receptors ] | |||
[http://en.wikipedia.org/wiki/Glutamate_receptor Glutamate signaling pathway and receptors general overview] | |||
[http://www.en.wikipedia.org/wiki/Gq_alpha_subunit] | [http://www.en.wikipedia.org/wiki/Gq_alpha_subunit] | ||
